"Cisplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Descriptor ID |
D002945
|
MeSH Number(s) |
D01.210.375 D01.625.125 D01.710.100
|
Concept/Terms |
Cisplatin- Cisplatin
- cis-Diamminedichloroplatinum(II)
- Platinum Diamminodichloride
- Diamminodichloride, Platinum
- cis-Platinum
- cis Platinum
- Dichlorodiammineplatinum
- cis-Diamminedichloroplatinum
- cis Diamminedichloroplatinum
- cis-Dichlorodiammineplatinum(II)
|
Below are MeSH descriptors whose meaning is more general than "Cisplatin".
Below are MeSH descriptors whose meaning is more specific than "Cisplatin".
This graph shows the total number of publications written about "Cisplatin" by people in this website by year, and whether "Cisplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 10 | 20 | 30 |
1995 | 9 | 20 | 29 |
1996 | 5 | 18 | 23 |
1997 | 8 | 22 | 30 |
1998 | 8 | 28 | 36 |
1999 | 7 | 27 | 34 |
2000 | 7 | 17 | 24 |
2001 | 3 | 25 | 28 |
2002 | 5 | 28 | 33 |
2003 | 18 | 33 | 51 |
2004 | 5 | 38 | 43 |
2005 | 7 | 28 | 35 |
2006 | 8 | 31 | 39 |
2007 | 14 | 29 | 43 |
2008 | 17 | 32 | 49 |
2009 | 6 | 29 | 35 |
2010 | 9 | 28 | 37 |
2011 | 13 | 29 | 42 |
2012 | 10 | 23 | 33 |
2013 | 16 | 31 | 47 |
2014 | 12 | 30 | 42 |
2015 | 13 | 31 | 44 |
2016 | 12 | 24 | 36 |
2017 | 14 | 24 | 38 |
2018 | 14 | 13 | 27 |
2019 | 21 | 14 | 35 |
2020 | 8 | 23 | 31 |
2021 | 4 | 20 | 24 |
2022 | 3 | 20 | 23 |
2023 | 4 | 13 | 17 |
2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cisplatin" by people in Profiles.
-
p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer. BMC Cancer. 2024 Feb 19; 24(1):233.
-
Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model. ACS Biomater Sci Eng. 2024 Mar 11; 10(3):1646-1660.
-
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449.
-
FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. Clin Cancer Res. 2024 01 05; 30(1):187-197.
-
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 Nov 01; 9(11):1565-1573.
-
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
-
Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study. Int J Gynecol Cancer. 2023 09 04; 33(9):1359-1369.
-
Intranasally Administered MSC-Derived Extracellular Vesicles Reverse Cisplatin-Induced Cognitive Impairment. Int J Mol Sci. 2023 Jul 24; 24(14).
-
Unraveling the Benefit of Adjuvant Chemotherapy in Early-Stage Combined Small Cell Lung Cancer. Ann Thorac Surg. 2023 12; 116(6):1149.
-
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 09; 84(3):341-347.